Biogen Inc. (BIIB)
After hours:
| Previous close | 227.44 |
| Open | 210.84 |
| Bid | 210.98 x 100 |
| Ask | 211.33 x 100 |
| Day's range | 210.00 - 217.53 |
| 52-week range | 189.44 - 278.95 |
| Volume | |
| Avg. volume | 1,036,248 |
| Market cap | 30.746B |
| Beta (5Y monthly) | -0.04 |
| PE ratio (TTM) | 26.36 |
| EPS (TTM) | 8.01 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 280.13 |
Investor's Business DailyBiogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
Biogen stock tumbled Friday after European regulators rejected its Eisai-partnered Alzheimer's treatment, citing steep side effects.
Barrons.comEU Rejection of Alzheimer’s Drug Is Another Disappointment for Biogen
European drug regulators rejected Biogen and Eisai request for approval of their Alzheimer’s medicine Leqembi, pointing to safety and efficacy issues that U.S. regulators looked past when they granted the drug full approval last year. The European Medicines Agency said Friday that it had recommended to the European Commission that it refuse marketing authorization within the European Union for Leqembi because of the drug’s limited benefits and the significant risks associated with it. “The observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious adverse events associated with the medicine,” the EMA said in a new document.
ZacksThe Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.
